Request Appointment
622 W 168th StNew York, NY 10032
Overview of Dr. Amengual
Dr. Jennifer Amengual is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from New York Medical College and has been in practice 21 years. She is one of 384 doctors at New York-Presbyterian Hospital and one of 120 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. She has more than 50 publications and over 500 citings.
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2007 - 2010
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2004 - 2007
New York Medical CollegeClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2007 - 2027
American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
- Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Start of enrollment: 2013 Sep 09
- ACY-1215 for Relapsed/Refractory Lymphoid Malignancies Start of enrollment: 2014 Apr 02
- Join now to see all
Publications & Presentations
PubMed
- Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.Seda S Tolu, Caitlin Gribbin, Zhengming Chen, Madhav R Seshadri, Evelyn Orlando
Leukemia & Lymphoma. 2025-08-14 - Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphoma.Emily R Gordon, Seda Tolu, Brigit A Lapolla, Megan H Trager, Oluwaseyi Adeuyan
Leukemia & Lymphoma. 2025-08-11 - Retrospective evaluation of R-EPOCH in the frontline treatment of adult patients with PTLD after solid organ transplant.Brian Cuzzo, Maegan Ford, Saagar Jain, Hua-Jay Cherng, Evelyn Orlando
Blood Neoplasia. 2025-05-01
Abstracts/Posters
- Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT ActivatorsJennifer E Amengual, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 StudiesJennifer E. Amengual, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Pipeline Moves: Moderna’s Pandemic Influenza Vaccine Trial CompletesAugust 19th, 2024
Grant Support
- Columbia University Minority/Underserved Site NCI Community Oncology Research ProgramCOLUMBIA UNIVERSITY HEALTH SCIENCES2014–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
